PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

Bond M, Rogers G, Peters J, et al. The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model. Southampton (UK): NIHR Journals Library; 2012 Apr. (Health Technology Assessment, No. 16.21.)

7Other factors relevant to the NHS

The care and treatment of people with AD is complex and goes beyond the patient themselves to include carers to a degree not seen in many other conditions. The extra burden to the NHS, social care services and the economy posed by the ill health of carers because of suboptimal service provision for Alzheimer's patients is unknown, but must be considerable and growing. Unfortunately, none of the trials included in the clinical effectiveness systematic review measured the effects of AD on carers.

With respect to the economic evaluation, many of the factors that would often be mentioned as ‘other factors’ in this section, such as impact on carers, have already been highlighted in previous appraisals and directly considered in the modelling exercises. Such themes have been further pursued in the analysis in this report and are thus not mentioned here. Taking a wider societal perspective in the economic analyses is an issue that has been raised previously in relation to this topic. The reasons why such a broad perspective is not appropriate for the decisions made by NICE have already been clearly expressed and tested. To be consistent with this the main focus of analyses in this report has been from a NHS and PSS perspective. This is not to deny the value of taking a wider perspective in the context of other decisions outside NICE.

© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

Cover of The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model
The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model.
Health Technology Assessment, No. 16.21.
Bond M, Rogers G, Peters J, et al.
Southampton (UK): NIHR Journals Library; 2012 Apr.

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...